Progress in haemophilic care: ethical issues.
Care of haemophilic patients has dramatically improved during the past 40-50 years. Clotting factor concentrates have become much safer. Expensive treatments such as prophylaxis, immune-tolerance induction, the use of bypassing agents in inhibitor patients, and the replacement of joints have become available. However, there is still a shortage of factor concentrate, and we are yet to discover the
